GC4419 90mg
GTI-4419-301
Phase 3 small_molecule completed
Quick answer
GC4419 90mg for Oral Mucositis is a Phase 3 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Galera Therapeutics
- Indication
- Oral Mucositis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed